Interferon-α: Difference between revisions
(Text replacement - "* " to "*") |
Neil.m.young (talk | contribs) (Text replacement - "α2" to "α<sub>2</sub>") |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Variable depending on indication and formulation (interferon- | *Variable depending on indication and formulation (interferon-α<sub>2</sub>A, -α<sub>2</sub>B, -αn3, -alfacon, peginterferon α-2a, peginterferon α-2b) | ||
*Used to treat: | *Used to treat: | ||
**Chronic hepatitis B, chronic hepatitis C | **Chronic hepatitis B, chronic hepatitis C | ||
| Line 17: | Line 17: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Variable depending on indication and formulation (interferon- | *Variable depending on indication and formulation (interferon-α<sub>2</sub>A, -α<sub>2</sub>B, -αn1, -αn3, -alfacon) | ||
*Used to treat: | *Used to treat: | ||
**chronic myelogenous leukemia (Philadelphia chromosome positive) | **chronic myelogenous leukemia (Philadelphia chromosome positive) | ||
| Line 26: | Line 26: | ||
*[[Drug pregnancy categories|Pregnancy Rating]]: C. When used with ribavirin, may lead to fetal defects or fetal death | *[[Drug pregnancy categories|Pregnancy Rating]]: C. When used with ribavirin, may lead to fetal defects or fetal death | ||
*Lactation risk: Infant risk cannot be ruled out | *Lactation risk: Infant risk cannot be ruled out | ||
*Renal dosing: IFN- | *Renal dosing: IFN-α<sub>2</sub>B and pegylated IFN-α<sub>2</sub>B contraindicated if CrCl <50 | ||
*Hepatic dosing: contraindicated in decompensated liver disease | *Hepatic dosing: contraindicated in decompensated liver disease | ||
| Line 75: | Line 75: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 2 to 160h | *Half-life: 2 to 160h | ||
*Metabolism: Hepatic, renal (IFN- | *Metabolism: Hepatic, renal (IFN-α<sub>2</sub>A) | ||
*Excretion: Renal | *Excretion: Renal | ||
Latest revision as of 23:31, 8 August 2017
Administration
- Type: Antiviral, antineoplastic
- Dosage Forms:
- Routes of Administration: Injection
- Common Trade Names:
Adult Dosing
- Variable depending on indication and formulation (interferon-α2A, -α2B, -αn3, -alfacon, peginterferon α-2a, peginterferon α-2b)
- Used to treat:
- Chronic hepatitis B, chronic hepatitis C
- Polycythemia vera, essential thrombocytopenia
- Condyloma acuminatum (refractory/recurrent)
- Kaposi's sarcoma, Malignant melanoma (adjunct)
- Carcinoid tumor
- Multiple myeloma, hairy cell leukemia, follicular lymphoma, chronic myelogenous leukemia (Philadelphia chromosome positive)
- Metastatic renal cell carcinoma
Pediatric Dosing
- Variable depending on indication and formulation (interferon-α2A, -α2B, -αn1, -αn3, -alfacon)
- Used to treat:
- chronic myelogenous leukemia (Philadelphia chromosome positive)
- Chronic hepatitis B, chronic hepatitis C
- Papillomatosis (adjunct)
Special Populations
- Pregnancy Rating: C. When used with ribavirin, may lead to fetal defects or fetal death
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: IFN-α2B and pegylated IFN-α2B contraindicated if CrCl <50
- Hepatic dosing: contraindicated in decompensated liver disease
Contraindications
- Allergy to class/drug or inactive ingredients: may contain benzyl peroxide, bovine/ovine Ig, mouse IgG, polymyxin B, neomycin, egg protein
- Autoimmune hepatitis
- Decompensated liver disease
- Hemoglobinopathies (e.g. thalassemia major, sickle cell) when used with ribavirin
- Pregnancy or men with pregnant female partners (in combination with ribavirin)
Adverse Reactions
Serious
- Dysrhythmia, hypotension, cardiomyopathy, MI
- Raynaud's disease, vasculitis
- Diabetes, hypertriglyceridemia, decreased body growth
- GI bleed, ischemic colitis
- Pancreatitis
- Anemia, aplastic anemia, thrombocytopenia, lymphocytopenia, neutropenia
- TTP
- Hepatotoxicity
- Autoimmune disease, lupus
- Rhabdomyolysis, myositis
- Stroke, cerebral hemorrhage, coma, encephalopathy
- Seizure
- Visual loss, optic neuritis, retinal hemorrhage, retinal artery/vein thrombosis
- Suicidal ideation/behavior, depression, psychotic disorder, agressive behavior
- Obliterative bronchiolitis, pneumonitis, pneumothorax, PE, pulmonary hypertension, sarcoidosis
- Erythroderma, Stevens-Johnson syndrome
- Infection
Common
- Alopecia
- Dermatitis, pruritus, dry skin, injection site reaction
- Weight loss
- Nausea/vomiting, abdominal pain, diarrhea, anorexia,
- Neutropenia
- Elevated AST/SGOT
- Thyroid dysfunction
- Musculoskeletal pain
- Asthenia, dizziness, fatigue, paresthesias
- Headache
- Depression, anxiety
- Cough dyspnea
- Edema
- Fever, influenza-like illness
Pharmacology
- Half-life: 2 to 160h
- Metabolism: Hepatic, renal (IFN-α2A)
- Excretion: Renal
Mechanism of Action
- Interferons induce various cell activities, such as antiviral activity, suppression of cell proliferation, augmentation of macrophage activity and other immunomodulating effects.